Novelty of Active Ingredients in High-Cost Brand-Name Drugs

J Gen Intern Med. 2020 Jul;35(7):2219-2221. doi: 10.1007/s11606-019-05565-8. Epub 2020 Jan 2.

Authors

Emily H Jung¹, Ameet Sarpatwari¹, Aaron S Kesselheim²

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. akesselheim@partners.org.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Drug Costs*
Drugs, Generic*
Humans

Substances

Drugs, Generic